Chelsea Therapeutics (CHTP) -24.1% premarket after announcing a clinical study of its...

|About: Chelsea Therapeutics Intern... (CHTP)|By:, SA News Editor

Chelsea Therapeutics (CHTP) -24.1% premarket after announcing a clinical study of its investigational rheumatoid arthritis treatment CH-4051 missed a primary endpoint, and the drug maker says it has no further plans to develop the medication.